NASDAQ: JUNSJupiter Neurosciences Inc Stock
$1.31-0.07 (-5.07%)
Updated Nov 13, 2025
JUNS Price
$1.31
Fair Value Price
$0.12
Market Cap
$45.63M
52 Week Low
$0.51
52 Week High
$19.51
P/E
-6.89x
P/B
34.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.96
Operating Cash Flow
-$6M
Beta
0.14
Next Earnings
Dec 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A
JUNS Overview
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine JUNS's potential to beat the market
- JUNS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
JUNS
RankedUnranked of 484
RankedUnranked of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.47 | A | |
| $105.41 | A | |
| $15.22 | A |
Be the first to know about important JUNS news, forecast changes, insider trades & much more!
JUNS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JUNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JUNS ($1.31) is overvalued by 961.61% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
JUNS ($1.31) is not significantly undervalued (961.61%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
JUNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more JUNS due diligence checks available for Premium users.
Valuation
JUNS fair value
Fair Value of JUNS stock based on Discounted Cash Flow (DCF)
Price
$1.31
Fair Value
$0.12
Overvalued by
961.61%
JUNS ($1.31) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
JUNS ($1.31) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
JUNS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JUNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.89x
Industry
287.59x
Market
44.95x
JUNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
34.05x
Industry
5.06x
JUNS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JUNS's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
JUNS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.0M
Liabilities
$2.6M
Debt to equity
1.96
JUNS's short-term assets ($2.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JUNS's short-term assets ($2.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JUNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$828.2k
Investing
$0.0
Financing
$0.0
JUNS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JUNS vs Biotech Stocks
Jupiter Neurosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.